Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Bullboard Posts
Comment by KILOFINALon Aug 05, 2020 7:23am
89 Views
Post# 31365355

RE:RE:looks like go !

RE:RE:looks like go !thanks for posting 


mariarose wrote:
Therma Bright Inc
Symbol THRM
Shares Issued 163,755,622
Close 2020-08-04 C$ 0.22
Recent Sedar Documents

 

Therma Bright, Orpheus Medica letter of intent

 

2020-08-04 18:48 ET - Miscellaneous

 

The TSX Venture Exchange has accepted for filing documentation pertaining to a binding letter of intent dated July 6, 2020, between Therma Bright Inc. and an arm's-length vendor, Orpheus Medica Inc. Pursuant to the agreement, the company will partner with Orpheus in the development of a rapid saliva test for the detection of the virus (SARS-CoV-2) causing COVID-19 (the project). The company will provide financing in phases to Orpheus for the project, based on the achievement of certain milestones. 

As consideration for the initial phase 1 of the project, the company will issue one million common shares and one million share purchase warrants to Orpheus. Each warrant entitles the holder to acquire one common share at a price of five cents for a five-year period. Further financing in the amount of up to $1-million may be provided by the company for phase 2 and phase 3 of the project, based on the achievement of the predefined milestones.

For further details, please refer to the company's news release dated July 7, 2020.

© 2020 Canjex Publishing Ltd. All rights reserved

https://www.stockwatch.com/News/Item?bid=Z-C%3aTHRM-2943206&symbol=THRM&region=C



Bullboard Posts